JNJ Johnson & Johnson
Research report · from SEC EDGAR · close 2026-07-10
$256.98 -0.8%
$618.61B mkt cap
executive summary
Johnson & Johnson (JNJ) is a $618.61B company. Revenue is $94.19B (+6.0% y/y) at a 28% net margin. It is profitable. Our health score is C (64/100). No major red flags on file. Smart money is buying (1 Congress). It funds itself; low dilution risk.
Revenue (FY)
$94.19B
+6.0% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 4
Cash & ST investments
$22.05B
Operating cash flow
$24.53B
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-10 by stocktools.ai.